Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
作者信息
Weatherald Jason, Boucly Athénaïs, Savale Laurent, Jaïs Xavier, Montani David, Humbert Marc, Sitbon Olivier
机构信息
University of CalgaryCalgary Alberta, Canada.
Libin Cardiovascular Institute Calgary, Alberta, Canada.
出版信息
Am J Respir Crit Care Med. 2021 Feb 15;203(4):524-525. doi: 10.1164/rccm.202009-3664LE.
Abstract
摘要
相似文献
1
Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?肺动脉高压中的肺血管阻力：关键因素？
Am J Respir Crit Care Med. 2021 Feb 15;203(4):524-525. doi: 10.1164/rccm.202009-3664LE.
2
Reply to Weatherald : Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?对韦瑟罗尔德的回复：肺动脉高压中的肺血管阻力：关键因素？
Am J Respir Crit Care Med. 2021 Feb 15;203(4):525-526. doi: 10.1164/rccm.202010-3834LE.
3
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.肺血管阻力在肺动脉高压患者中的临床应用
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
4
Adding an important piece to the pulmonary vascular resistance puzzle in pulmonary arterial hypertension.为肺动脉高压中肺血管阻力难题增添了重要一环。
Eur Respir J. 2020 Jul 9;56(1). doi: 10.1183/13993003.00962-2020. Print 2020 Jul.
5
A Change in Focus.重点的转变。
Circ Cardiovasc Imaging. 2019 May;12(5):e009186. doi: 10.1161/CIRCIMAGING.119.009186.
6
Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension.血吸虫病相关性肺动脉高压中动脉血管容量随血流动力学的变化
Eur Respir J. 2021 May 6;57(5). doi: 10.1183/13993003.03914-2020. Print 2021 May.
7
Assessing the cancer hypothesis of pulmonary arterial hypertension: the devil is in the detail.评估肺动脉高压的癌症假说：细节决定成败。
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1140-L1141. doi: 10.1152/ajplung.00084.2020. Epub 2020 Mar 18.
8
Call it by the correct name-pulmonary hypertension not pulmonary arterial hypertension: growing recognition of the global health impact for a well-recognized condition and the role of the Pulmonary Vascular Research Institute.用正确的名称称呼它——肺动脉高压而非动脉性肺动脉高压：对一种广为人知的疾病的全球健康影响以及肺血管研究所的作用的认识不断提高。
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L992-L994. doi: 10.1152/ajplung.00098.2020. Epub 2020 Apr 1.
9
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle.降低肺动脉高压的压力：索他洛尔、血流动力学与右心室
Eur Respir J. 2023 Sep 21;62(3). doi: 10.1183/13993003.01513-2023. Print 2023 Sep.
10
When "AMBITION" Isn't Good Enough: Risk Status and Dual Oral Therapy in Pulmonary Arterial Hypertension.当“雄心壮志”还不够时：肺动脉高压的风险状况与双重口服疗法
Am J Respir Crit Care Med. 2021 Feb 15;203(4):410-411. doi: 10.1164/rccm.202008-3313ED.
本文引用的文献
1
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.肺动脉高压初始联合治疗的风险降低与血液动力学。
Am J Respir Crit Care Med. 2021 Feb 15;203(4):484-492. doi: 10.1164/rccm.202004-1006OC.
2
Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.肺动脉高压的 upfront 三联疗法可降低风险和逆转右心重构。
Chest. 2020 Feb;157(2):376-383. doi: 10.1016/j.chest.2019.09.009. Epub 2019 Sep 26.
3
Seeing the Forest for the (Arterial) Tree: Vascular Pruning and the Chronic Obstructive Pulmonary Disease Pulmonary Vascular Phenotype.透过（动脉）树木见森林：血管修剪与慢性阻塞性肺疾病的肺血管表型
Am J Respir Crit Care Med. 2019 Aug 15;200(4):406-408. doi: 10.1164/rccm.201901-0248ED.
4
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.预测肺动脉高压患者的生存情况：REVEAL 风险评分计算器 2.0 与 ESC/ERS 风险评估策略的比较。
Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
5
Risk stratification and medical therapy of pulmonary arterial hypertension.肺动脉高压的风险分层与药物治疗。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01889-2018. Print 2019 Jan.
6
Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.系统性硬皮病相关肺动脉高压的血液动力学和连续风险评估。
Eur Respir J. 2018 Oct 18;52(4). doi: 10.1183/13993003.00678-2018. Print 2018 Oct.
7
The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?肺动脉高压的低风险特征。是时候向以目标为导向的临床试验终点进行范式转变了吗？
Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP.
8
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.初始治疗后随访血流动力学变量对肺动脉高压的预后价值。
Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.
9
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.肺动脉高压的风险评估、预后和指南实施。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017. Print 2017 Aug.
10
Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. upfront 三联疗法在肺动脉高压中的应用：一项初步研究。
Eur Respir J. 2014 Jun;43(6):1691-7. doi: 10.1183/09031936.00116313. Epub 2014 Mar 13.
Zotero 插件